Serpin-independent anticoagulant activity of a fucosylated chondroitin sulfate

被引:63
作者
Glauser, Bianca F. [1 ,2 ]
Pereira, Mariana S. [1 ,3 ]
Monteiro, Robson Q. [2 ]
Mourao, Paulo A. S. [1 ,2 ]
机构
[1] Univ Fed Rio de Janeiro, Lab Tecido Conjuct, Hosp Univ Clementino Fraga Filho, BR-21941590 Rio De Janeiro, Brazil
[2] Univ Fed Rio de Janeiro, Inst Bioquim Med, BR-21941590 Rio De Janeiro, Brazil
[3] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, BR-21941590 Rio De Janeiro, Brazil
关键词
glycosaminoglycan; tenase complex; prothrombinase complex; sea cucumber; heparin;
D O I
10.1160/TH08-04-0210
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fucosylated chondroitin sulfate is a glycosaminoglycan from sea cucumber composed of a chondroitin sulfate-like core with branches of sulfated fucose. This glycosaminoglycan has high anticoagulant and antithrombotic activities. Its serpin-dependent anticoagulant activity is mostly due to activating thrombin inhibition by heparin cofactor II. Here,we evaluated the anticoagulant activity of fucosylated chondroitin sulfate using antithrombin-and heparin cofactor II-free plasmas. In contrast to mammalian heparin, the invertebrate glycosaminoglycan is still able to prolong coagulation time and delay thrombin and factor Xa generation in serpin-free plasmas. These observations suggest that fucosylated chondroitin sulfate has a serpin-independent anticoagulant effect. We further investigated this effect using purified blood coagulation proteins. Clearly, fucosylated chondroitin sulfate inhibits the intrinsic tenase and prothrombinase complexes, which are critical for thrombin generation. It is possible that the invertebrate chondroitin sulfate inhibits interactions between cofactor Va and factor Xa. We also employed chemically modified polysaccharides in order to trace a structure versus activity relationship. Removal of the sulfated fucose branches, but not reduction of the glucuronic acid residues to glucose, abolished its activity. In conclusion, fucosylated chondroitin sulfate has broader effects on the coagulation system than mammalian glycosaminoglycans. In addition to its serpin-dependent inhibition of coagulation protease, it also inhibits the generation of factor Xa and thrombin by the tenase and prothrombinase complexes, respectively. In plasma systems,the serpin-independent anticoagulant effect of fucosylated chondroitin sulfate predominates over its serpin-dependent action. This glycosaminoglycan opens new avenues for the development of antithrombotic agents.
引用
收藏
页码:420 / 428
页数:9
相关论文
共 37 条
[1]  
*AM HEART ASS, 2002, HEART STROK
[2]   Hypersulfated low molecular weight heparin with reduced affinity for antithrombin acts as an anticoagulant by inhibiting intrinsic tenase and prothrombinase [J].
Anderson, JAM ;
Fredenburgh, JC ;
Stafford, AR ;
Guo, YS ;
Hirsh, J ;
Ghazarossian, V ;
Weitz, JI .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (13) :9755-9761
[3]  
ASTERMARK J, 1992, J BIOL CHEM, V267, P3249
[4]  
BARROW RT, 1994, J BIOL CHEM, V269, P26796
[5]   New anticoagulants: Anti IIa vs anti Xa - Is one better? [J].
Bauer, KA .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2006, 21 (01) :67-72
[6]  
Bauer Kenneth A, 2006, Hematology Am Soc Hematol Educ Program, P450
[7]   MECHANISM OF THE ANTICOAGULANT ACTION OF HEPARIN [J].
BJORK, I ;
LINDAHL, U .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 1982, 48 (03) :161-182
[8]   LACK OF RELATIONSHIP BETWEEN ENHANCED BLEEDING INDUCED BY HEPARIN AND OTHER SULFATED POLYSACCHARIDES AND ENHANCED CATALYSIS OF THROMBIN INHIBITION [J].
BUCHANAN, MR ;
OFOSU, FA ;
FERNANDEZ, F ;
VANRYN, J .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1986, 12 (04) :324-327
[9]  
Butenas S, 2002, BIOCHEMISTRY-MOSCOW+, V67, P3
[10]   A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement:: the BISTRO II randomized trial [J].
Eriksson, BI ;
Dahl, OE ;
Büller, HR ;
Hettiarachchi, R ;
Rosencher, N ;
Bravo, ML ;
Ahnfelt, L ;
Piovella, F ;
Stangier, J ;
Kälebo, P ;
Reilly, P .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (01) :103-111